JournalFrontiers in Immunology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractIn recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection. Copyright 2019 The Authors.
SponsorsThis work was supported in part by the Intramural Research Program of NIAID, NIH, National Institutes of Health 1R01AI123820-01 (DG), and the International Centre for Cancer Vaccine Science project of the International Research Agendas program of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund (MAB/2017/03) at the University of Gdansk (ZU-W, NM-T, RF, DG, and TH).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85074564849&doi=10.3389%2ffimmu.2019.02388&partnerID=40&md5=60cb9f7ec741664a21e69e7280c9a91b; http://hdl.handle.net/10713/11430